Skip to Content

Vaxart Inc VXRT

Morningstar Rating
$1.30 +0.01 (0.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VXRT is trading at a 48% discount.
Price
$1.24
Fair Value
$3.83
Uncertainty
Extreme
1-Star Price
$97.84
5-Star Price
$9.47
Economic Moat
Zcf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VXRT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.29
Day Range
$1.281.41
52-Week Range
$0.531.59
Bid/Ask
$1.28 / $1.30
Market Cap
$226.02 Mil
Volume/Avg
2.8 Mil / 1.9 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
25.51
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
109

Comparables

Valuation

Metric
VXRT
PCVX
AVIR
Price/Earnings (Normalized)
Price/Book Value
3.455.250.61
Price/Sales
25.51
Price/Cash Flow
Price/Earnings
VXRT
PCVX
AVIR

Financial Strength

Metric
VXRT
PCVX
AVIR
Quick Ratio
3.117.4317.86
Current Ratio
3.327.5418.24
Interest Coverage
−57.64
Quick Ratio
VXRT
PCVX
AVIR

Profitability

Metric
VXRT
PCVX
AVIR
Return on Assets (Normalized)
−59.01%−21.69%−15.46%
Return on Equity (Normalized)
−85.90%−23.31%−16.16%
Return on Invested Capital (Normalized)
−69.50%−28.13%−19.92%
Return on Assets
VXRT
PCVX
AVIR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGjztdqvcjpJbty$570.1 Bil
VRTX
Vertex Pharmaceuticals IncXgrbccxwnHpclqx$108.0 Bil
REGN
Regeneron Pharmaceuticals IncPgjnzxbcYyzgrjd$105.6 Bil
MRNA
Moderna IncZjgddvlpHlgxx$40.8 Bil
ARGX
argenx SE ADRHcxffxjfWxvpc$23.5 Bil
BNTX
BioNTech SE ADRLgrcfbhgmTpxdg$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncRjqmvcfVlmrjt$18.8 Bil
BMRN
Biomarin Pharmaceutical IncWwtdcscrPxkxbbp$16.5 Bil
RPRX
Royalty Pharma PLC Class ATqhyqxnyKplrzss$13.6 Bil
INCY
Incyte CorpTdlmwdfbTkbmpv$12.8 Bil

Sponsor Center